RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsThis week Pfizer's CEO stated at Davos Switzerland conference of world leaders that Pfizer is "interested in smaller acquisitions of “breakthrough” science and medicines.
..... which aligns with what has been posted on this subject in the recent past on how pharma's US$ 5 Bln - $15 Bln "sweet spot" is in play versus the $60 - $70 Bln mega deal.